Breast Neoplasms, Neoplasm Metastasis
Conditions
Keywords
First Line Metastatic Breast Cancer
Brief summary
This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.
Interventions
30 minute infusions
DRUGbevacizumab
infusions
Sponsors
Celgene
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed adenocarcinoma of the breast. * Stage IV disease * Measurable disease * Patients must not be a candidate for Herceptin therapy * At least 4 weeks since radiotherapy, with full recovery. The measurable disease must be completely outside the radiation portal or there must be pathologic proof of progressive disease within the radiation portal. * At least 4 weeks since major surgery, with full recovery. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Female \>18 years of age. * Patient has the following blood counts at Baseline: Absolute neutrophil count ≥ 1.5 x 10\^9cells/L; platelets ≥ 100 x 10\^9 cells/L; hemoglobin ≥ 9 g/dL. * Patient has the following blood chemistry levels at Baseline: Aspartate transaminase (AST or SGOT), alanine aminotransferase (ALT or SGPT) ≤ 2.5x upper limit of normal range (ULN); total bilirubin ≤ ULN; creatinine ≤ 1.5 mg/dL. * If female of childbearing potential, pregnancy test is negative within 72 hours of first dose of study drug. * If fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study. * Informed consent has been obtained.
Exclusion criteria
* Prior neo-adjuvant or adjuvant chemotherapy is allowed, and patients must have recovered from the acute toxicity of such therapies. No prior therapy for metastatic disease is allowed. If a taxane was part of the adjuvant regimen, at least 12 months should have passed from completion of taxane regimen to relapse. If a non-taxane-based adjuvant therapy was administered, at least 6 months should have passed from completion to relapse. * Concurrent immunotherapy or hormonal therapy. * Parenchymal brain metastases, including leptomeningeal involvement. * Inadequately controlled hypertension (defined as blood pressure of \> 150/100 mmHg) or New York Heart Association (NYHA) Grade 2 or greater congestive heart failure. * Any prior history of hypertensive crisis or hypertensive encephalopathy. * History of myocardial infarction or unstable angina within 6 months prior to study enrollment. * History of stroke or transient ischemic attack within 6 months prior to study enrollment. * Significant vascular disease (e.g., aortic aneurysm, aortic dissection). * Symptomatic peripheral vascular disease. * Evidence of bleeding diathesis or coagulopathy. * History of abdominal fistula, gastrointestinal perforation, or intra- abdominal abscess within 6 months prior to study enrollment. * Proteinuria at screening as demonstrated by either: - Urine protein:creatinine (UPC) ratio \> 1.0 at screening OR - Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible). * Known hypersensitivity to any component of bevacizumab. * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to first dose. * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to first dose, anticipation of need for major surgical procedure during the course of the study. Serious, non-healing wound, ulcer, or bone fracture. Serious intercurrent medical or psychiatric illness, including serious active infection. * History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer. * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study. * Pregnant or nursing women. * Sensory neuropathy of \> Grade 1 at baseline.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Participants With a Dose Interruption of ABI-007 | Up to 53 months | Number of participants who interrupted (omitted) a dose at some point in the treatment period. This outcome is considered to be both a safety and an efficacy outcome. |
| Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | up to 54 months | Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) WBC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal -3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L |
| Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | up to 54 months | Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) platelet counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L |
| Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | up to 54 months | Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) hemoglobin levels were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100g/L; Grade 2 = \<100 - 80g/L; Grade 3 = \<80 - 65g/L; Grade 4 = \<65g/L |
| The Number of Participants With at Least One Dose Reduction for ABI-007 | Up to 53 months | Participants with at least one dose reduction for ABI-007. ABI-007 (Abraxane) dose could be reduced according to protocol guidelines if the participant was experiencing toxicities. Participants were allowed two ABI-007 (Abraxane) dose reductions during the course of the trial. This outcome is considered to be both a safety and an efficacy outcome. |
| The Number of Participants With at Least One Dose Delay for ABI-007 | Up to 53 months | Participants with at least one dose delay for ABI-007. Treatment delays of no longer than 2 weeks allowed participants to recovery from acute toxicity. If treatment was delayed beyond 2 weeks, continuing treatment on protocol was at the physician's discretion, based upon the best interests of the participant. This outcome is considered to be both a safety and an efficacy outcome. |
| The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | Up to 43 months | Using the RECIST response criteria version 1.0, the percent of participants achieving either a complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the investigator assessment of best overall response during study treatment. |
| Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | up to 54 months | Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) ANC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9L; Grade 2 = \<1.5 - 1.0\*10\^9L; Grade 3 = \<1.0 - 0.5\*10\^9L; Grade 4 = \<0.5\*10\^9L |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Kaplan Meier Estimate for Time to Disease Progression (TTP) | Up to 43 months (until progressed) | Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. |
| Kaplan Meier Estimate for Duration of Response | Up to 43 months (until progressed) | Duration of response was defined as the time from response to the time of disease progression for participants who achieve an objective confirmed complete (CR) or partial overall response (PR). Disease progression is based on the assessments by the investigator. Participants who did not have disease progression following a confirmed complete or partial target response were censored at the last known time that the participant was evaluated for response |
| Kaplan Meier Estimate for Participant Survival | Up to 56 months | Participant survival was summarized using Kaplan-Meier estimate of the time of first dose of study drug to the last known time that the participant was alive. Participants that were alive at the end of follow-up would be censored at the last known time that the patient was alive. |
| Kaplan Meier Estimate for Progression-Free Survival (PFS) | up to 56 months | PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. |
| Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | Up to 43 months (until progressed) | Using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), the percentage of participants achieving either * A complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or * A partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions or * Stable disease (SD) defined as neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for progressive disease. |
Countries
Puerto Rico, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks 260 mg/m\^2 of ABI-007 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks. | 75 |
| 260 mg/m^2 ABI-007 Every 2 Weeks 260 mg/m\^2 of ABI-007 every two weeks and 10 mg/kg bevacizumab every 2 weeks | 54 |
| 130 mg/m^2 ABI-007 Weekly 130 mg/m\^2 of ABI-007 every week and 10 mg/kg bevacizumab every 2 weeks | 79 |
| Total | 208 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event-unrelated to treatment | 3 | 0 | 2 |
| Overall Study | Other | 6 | 3 | 5 |
| Overall Study | Physician Decision | 11 | 4 | 5 |
| Overall Study | Progressive Disease | 28 | 18 | 27 |
| Overall Study | Protocol Violation | 1 | 0 | 1 |
| Overall Study | Unacceptable Toxicity-related to trt | 21 | 24 | 32 |
| Overall Study | Withdrawal by Subject | 5 | 5 | 7 |
Baseline characteristics
| Characteristic | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 22 Participants | 13 Participants | 16 Participants | 51 Participants |
| Age, Categorical Between 18 and 65 years | 53 Participants | 41 Participants | 63 Participants | 157 Participants |
| Age, Customized | 59.0 Years | 56.0 Years | 56.0 Years | 57.0 Years |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 0 | 43 Participants | 33 Participants | 48 Participants | 124 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 1 | 29 Participants | 17 Participants | 27 Participants | 73 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 2 | 3 Participants | 4 Participants | 4 Participants | 11 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 3 | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 4 | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Menopausal status Post-menopausal | 64 Participants | 43 Participants | 63 Participants | 170 Participants |
| Menopausal status Pre-menopausal | 11 Participants | 11 Participants | 16 Participants | 38 Participants |
| Participants with Current Diagnosis at Stage IV | 75 Participants | 54 Participants | 79 Participants | 208 Participants |
| Race/Ethnicity, Customized Asian | 1 Participants | 0 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Black, of African Heritage | 11 Participants | 13 Participants | 19 Participants | 43 Participants |
| Race/Ethnicity, Customized Other (not specified) | 3 Participants | 0 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized White, Hispanic or Latino | 8 Participants | 10 Participants | 14 Participants | 32 Participants |
| Race/Ethnicity, Customized White, Non-Hispanic and Non-Latino | 52 Participants | 31 Participants | 45 Participants | 128 Participants |
| Sex: Female, Male Female | 75 Participants | 54 Participants | 79 Participants | 208 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Time from Primary Diagnosis to Study Entry | 4.320 Years | 3.127 Years | 2.579 Years | 2.983 Years |
| Weight | 72.9 kilograms | 70.2 kilograms | 73.1 kilograms | 72.2 kilograms |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 75 / 75 | 54 / 54 | 78 / 79 |
| serious Total, serious adverse events | 22 / 75 | 16 / 54 | 32 / 79 |
Outcome results
Primary
Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) ANC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9L; Grade 2 = \<1.5 - 1.0\*10\^9L; Grade 3 = \<1.0 - 0.5\*10\^9L; Grade 4 = \<0.5\*10\^9L
Time frame: up to 54 months
Population: Treated population who had at least one post baseline value
| Arm | Measure | Group | Value (NUMBER) | Dispersion |
|---|---|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 3 participants | — |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 2 participants | — |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 51 participants | 1.569 |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 5 participants | — |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 2 participants | — |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 6 participants | — |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 34 participants | 3.216 |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 5 participants | — |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 4 participants | — |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 0 participants | — |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 2 participants | — |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 17 participants | — |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 17 participants | 0.75 |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 17 participants | — |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 17 participants | — |
Primary
Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) hemoglobin levels were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100g/L; Grade 2 = \<100 - 80g/L; Grade 3 = \<80 - 65g/L; Grade 4 = \<65g/L
Time frame: up to 54 months
Population: Treated population who had at least one post baseline value
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 0 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 6 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 41 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 17 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 0 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 6 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 25 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 18 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 0 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 0 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 1 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 4 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 13 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 19 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 33 participants |
Primary
Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) platelet counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L
Time frame: up to 54 months
Population: Treated population who had at least one post baseline value
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 0 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 1 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 60 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 2 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 0 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 0 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 39 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 10 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 0 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 0 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 0 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 0 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 64 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 1 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 4 participants |
Primary
Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) WBC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal -3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L
Time frame: up to 54 months
Population: Treated population who had at least one post baseline value
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 2 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 6 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 47 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 9 participants |
| 260 mg/m^2 ABI-007 Every 3 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 0 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 5 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 30 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 14 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 0 participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 0 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 4 | 1 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 3 | 11 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 0 | 11 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 2 | 26 participants |
| 130 mg/m^2 ABI-007 Weekly | Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3) | Grade 1 | 21 participants |
Primary
The Number of Participants With a Dose Interruption of ABI-007
Number of participants who interrupted (omitted) a dose at some point in the treatment period. This outcome is considered to be both a safety and an efficacy outcome.
Time frame: Up to 53 months
Population: Treated population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | The Number of Participants With a Dose Interruption of ABI-007 | 2 Participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | The Number of Participants With a Dose Interruption of ABI-007 | 0 Participants |
| 130 mg/m^2 ABI-007 Weekly | The Number of Participants With a Dose Interruption of ABI-007 | 0 Participants |
Primary
The Number of Participants With at Least One Dose Delay for ABI-007
Participants with at least one dose delay for ABI-007. Treatment delays of no longer than 2 weeks allowed participants to recovery from acute toxicity. If treatment was delayed beyond 2 weeks, continuing treatment on protocol was at the physician's discretion, based upon the best interests of the participant. This outcome is considered to be both a safety and an efficacy outcome.
Time frame: Up to 53 months
Population: Treated population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | The Number of Participants With at Least One Dose Delay for ABI-007 | 40 Participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | The Number of Participants With at Least One Dose Delay for ABI-007 | 27 Participants |
| 130 mg/m^2 ABI-007 Weekly | The Number of Participants With at Least One Dose Delay for ABI-007 | 68 Participants |
Primary
The Number of Participants With at Least One Dose Reduction for ABI-007
Participants with at least one dose reduction for ABI-007. ABI-007 (Abraxane) dose could be reduced according to protocol guidelines if the participant was experiencing toxicities. Participants were allowed two ABI-007 (Abraxane) dose reductions during the course of the trial. This outcome is considered to be both a safety and an efficacy outcome.
Time frame: Up to 53 months
Population: Treated population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | The Number of Participants With at Least One Dose Reduction for ABI-007 | 36 Participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | The Number of Participants With at Least One Dose Reduction for ABI-007 | 32 Participants |
| 130 mg/m^2 ABI-007 Weekly | The Number of Participants With at Least One Dose Reduction for ABI-007 | 53 Participants |
Primary
The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)
Using the RECIST response criteria version 1.0, the percent of participants achieving either a complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the investigator assessment of best overall response during study treatment.
Time frame: Up to 43 months
Population: Treated population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | 41 Percent of Total Participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | 43 Percent of Total Participants |
| 130 mg/m^2 ABI-007 Weekly | The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | 47 Percent of Total Participants |
p-value: 0.4476Cochran-Mantel-Haenszel
Secondary
Kaplan Meier Estimate for Duration of Response
Duration of response was defined as the time from response to the time of disease progression for participants who achieve an objective confirmed complete (CR) or partial overall response (PR). Disease progression is based on the assessments by the investigator. Participants who did not have disease progression following a confirmed complete or partial target response were censored at the last known time that the participant was evaluated for response
Time frame: Up to 43 months (until progressed)
Population: Treated population who achieved a complete or partial response
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | Kaplan Meier Estimate for Duration of Response | 10.3 Months |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Kaplan Meier Estimate for Duration of Response | 8.0 Months |
| 130 mg/m^2 ABI-007 Weekly | Kaplan Meier Estimate for Duration of Response | 9.9 Months |
Secondary
Kaplan Meier Estimate for Participant Survival
Participant survival was summarized using Kaplan-Meier estimate of the time of first dose of study drug to the last known time that the participant was alive. Participants that were alive at the end of follow-up would be censored at the last known time that the patient was alive.
Time frame: Up to 56 months
Population: Treated population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | Kaplan Meier Estimate for Participant Survival | 21.3 Months |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Kaplan Meier Estimate for Participant Survival | 19.0 Months |
| 130 mg/m^2 ABI-007 Weekly | Kaplan Meier Estimate for Participant Survival | 23.7 Months |
Secondary
Kaplan Meier Estimate for Progression-Free Survival (PFS)
PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.
Time frame: up to 56 months
Population: Treated population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | Kaplan Meier Estimate for Progression-Free Survival (PFS) | 7.7 months |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Kaplan Meier Estimate for Progression-Free Survival (PFS) | 6.3 months |
| 130 mg/m^2 ABI-007 Weekly | Kaplan Meier Estimate for Progression-Free Survival (PFS) | 8.8 months |
Secondary
Kaplan Meier Estimate for Time to Disease Progression (TTP)
Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
Time frame: Up to 43 months (until progressed)
Population: Treated population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | Kaplan Meier Estimate for Time to Disease Progression (TTP) | 8.0 Months |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Kaplan Meier Estimate for Time to Disease Progression (TTP) | 6.3 Months |
| 130 mg/m^2 ABI-007 Weekly | Kaplan Meier Estimate for Time to Disease Progression (TTP) | 9.0 Months |
Secondary
Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)
Using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), the percentage of participants achieving either * A complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or * A partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions or * Stable disease (SD) defined as neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for progressive disease.
Time frame: Up to 43 months (until progressed)
Population: Treated population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | 65 Percent of Total Participants |
| 260 mg/m^2 ABI-007 Every 2 Weeks | Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | 52 Percent of Total Participants |
| 130 mg/m^2 ABI-007 Weekly | Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | 58 Percent of Total Participants |